Ian Mortimer, PRESIDENT, CEO & INTERIM CFO at Xenon Pharmaceuticals Inc. (XENE), sold 50,000 shares at $40.16 ($2.0M) on 2025-10-01, disclosed to the SEC on 2025-10-01.
Scheduled sale ($2.0M) by PRESIDENT, CEO & INTERIM CFO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $40.16 | 25,000 | $1.0M | 50.0% |
| 2 | $40.16 | 25,000 | $1.0M | 50.0% |
| Total | $40.16 avg | 50,000 | $2.0M | 100% |
| Filing → |
| XENE | SELL | 2026-03-11 | $17.6M | — | Filing → |
| XENE | SELL | 2026-01-02 | $1.8M | — | Filing → |
| XENE | SELL | 2025-12-09 | $2.3M | — | Filing → |